ATOM INDONESIA
Author's Responses
Article : #437
Name of All Authors : R.D. Haryuni1, M. Ramli1, Triningsih1, and Sutari 1
Article Title : Radiolabeled Antibody Fragment for Preparation of (177Lu-DOTA)m- PAMAM G3.0-F(ab’)2-trastuzumab as a Radiopharmaceutical for Cancer Therapy
E-mail : [email protected]
Line
# Referee’s Comments Author's Responses
2 trastuzumab as a Radiopharmaceutical for Cancer Therapy done
12-13
Several radiolabeled monoclonal antibodies (mAb’s) have been used as radioimmunotherapy (RIT) agents for cancer therapy.
The use of mAb as RIT agent is due to its ability to carry effectors, in the form of radionuclides which emit alpha (α), beta (β) particles or auger electrons, and bind specifically to cancer expressed targeted receptor. This paper reports reported the preparation of radiolabeled trastuzumab in the form of (177Lu)n- (DOTA)m-PAMAM-G3-F(ab')2-trastuzumab, which will be expected as a potential RIT agent for therapy of breast cancer overexpressed over expressed human epidermal growth factor receptor 2 (HER-2). Due to its downsized molecular weight, the use of F(ab')2-trastuzumab on the above–mentioned RIT agent candidate is expected to reaches its target much faster compared to the intact whole trastuzumab. Meanwhile, the use role of PAMAM-G3 is expected to increase the specific activity of the RIT radiotherapeutic agent of Lu-177 due to its ability of agent candidate as PAMAM-G3 which has 32 –NH2 functional groups that are able to bind many DOTA (≤ 31) which in turn would bind a large number of 177Lu. The preparation was initiated by fragmentation of trastuzumab using pepsin enzyme in 0.02 M acetic acid buffer pH 4.5 to give F(ab')2-trastuzumab with purity of 95% after purification with PD-10 column. The F(ab')2- trastuzumab was then reacted with succinimidyl 4-(N- maleimidomethyl) cyclohexane-1-carboxylate (SMCC) to give SMCC-F(ab ')2-trastuzumab. The next reaction was to conjugate SMCC-F(ab ')2-trastuzumab with DOTA-PAMAM-G3.0-SH, which was prepared by reaction NHS-DOTA with PAMAMG3.0 and followed by reacting it with 2-iminothiolane to give (DOTA)m-PAMAMG3.0-F(ab')2-trastuzumab. Finally, the (DOTA)m-PAMAM-G3.0-F(ab')2-trastuzumab was radiolabeled with a radionuclide of 177Lu to give (177Lu-DOTA)m- PAMAMG3.0-F(ab')2-trastuzumab (177Lu)n-(DOTA)m- PAMAMG3.0-F(ab')2-trastuzumab resulting in radiochemical purity of 98% after purification with PD-10 column.
done
18 ….incidence of death, cancer, and its prevalence
for…. done
25-26 …..(MAb) has long been used for cancer therapy; the target
is a tumor antigen. done
28 ……..transduction signal, blocking the receptor, reducing…..
done
32 …..which is loaded with a toxin, radioisotope or drug.
done
38-39 HER-2 is one of the family members of Epidermal Growth Factor Receptor (EGFR), which consists of HER-1, HER- 2, HER-3, and HER-4
done 42 ……. target, target because its level is closely…….. done 44-47
Also, In addition to breast cancer, overexpressions of HER-2 are found in others cancer other cancers, such as the pancreas, ovarian, and colorectal.
done
49 …..HER-2-positif positive tumor cell done
51 Radioimunotherapy Radioimmunotherapy (RIT) can be used
as……. done
52-53 ……treatment in which a radioisotop radioisotope that is
combined with done
69-72
mono Mono-N-hydroxysuccinimide ester1,4,7,10- tetraazacyclododecane-N,N’,N’,N’”-tetraacetic acid tetraaceticacid (NHS-DOTA) is an example of bifunctional chelating agent [9] utilized in this research.
done 74-75 Dendrimers are a monodisperse macromolecule, homogenous,
nano-sized [10],….. done
77-80
The structure of dendrimer that which includes molecular weight, size, and the amount of surface functional groups can be modified.
done
80-82
Therefore, dendrimer exists in the form of low to high generation namely dendrimer generation 1 (G1), G2, G3, and so on etc.[11)
done
85-88
These groups can be used to bind both a complex compounds, such as 177Lu-DOTA, and to a molecular carriers, such as trastuzumab [12].
done
90-92
This study aims at developing a new radioimmunotherapeutic agent radioimmunotherapy (RIT) of (177Lu-DOTA)m-
PAMAM-G3-F(ab')2-trastuzumab.
done 92-94 (DOTA)m-PAMAM-G3-F(ab')2-trastuzumab is synthesized
through four step reaction reaction steps ……….. done
112 ….. Multi-Purpose Reactor and ………. done
114- 115
…..National Nuclear Energy of Indonesia Indonesian National
Nuclear Energy Agency …. done
118- 120
….. sulfo-SMCC (Thermo Fisher Scientific) and Traut’s reagent of 2-iminothiolane (Thermo Fisher Scientific) from Thermo Fisher Scientific,.
done
120- 125
Bovine serum albumin, trizma base, ……….and tris-glysin tris glycine (Sigma) were purchased from Sigma, while EDTA, HCl, and NaOH were from E125 Merck (obtained from E125 Merck),.
done 125 Others were protein standard standart and protein dye (Bio- done
Rad),………
128- 129
Sephadex G25 Columns, GE Healthcare) and Instance thin layer
silica gel (ITLC-SC) strips (Agilent). done
134 Others were thermomixer and micropipette (Eppendorf), done 141-
142
After dialysis dyalisis process using dialysis cassette complete, aliquot liquot (100 μL) of digestion buffer was added to 0.75 mg pepsin.
done 144 …. properly propelly dissolved followed ………. done 147 …. 10 mM at mMat pH 8.0 was added to …..
done 152-
153
The fraction of with F(ab’)2-trastuzumab purity > 95% were
then pooled then used for further study. done
161- 162
PAMAM G 3.0 in 0.1 M phosphate buffer at pH 7.4 was added into sulfo NHS-DOTA solution in 0.1 M phosphate buffer (mol ratio 1: 96).
done 168-
172
All purification processes in this work project used PD-10 column which was pre-blocked with BSA, and equilibrated with the desired eluent, and The column was then eluted with 0.01 M
done 172-
173
The eluates from a purification step of (DOTA)m-PAMAM 3.0
conjugate were separated into 30 fractions of 0.25 mL each done
185- 192
Aliquot of 2- iminothiolane was added into PAMAM G 3.0 conjugate (DOTA)m-PAMAM G 3.0 cojugate with mol ratio of 2:1 followed by incubationat incubation at room temperature for 1 hr. under nitrogen gas atmosphere to form The DOTA)m- PAMAM G 3.0-SH that formed was then purified form
unreacted 2-iminothiolane using PD-10 column in similar to that of Sec. 3.1.
done
195 …….using the dye-protein. done
195- 197
Fractions, which gave a blue colour indicating the existence of (DOTA)m-PAMAM G 3.0-SH, were then retrieved and used for further study.
done 202-
205
Sulfo-SMCC was dissolved in a small amount of DMSO/DMF, and then the concentration was made to become 1 mg/ mL by addition of 0.1 M PBS at pH 7.4 (containing 5 mM EDTA).
done
208 ...incubation at incubationat room temperature for 30
minutes. done
211 …… (containing 5 mM EDTA) in a similar manner with
Section 3.1. done
214- 215
………and tested using the dye-protein dye protein.
done 223-
225
The activated DOTA- PAMAM G 3.0 [(DOTA)m-PAMAM G 3.0-SH] (DOTA)m-PAMAM G 3.0-SH was added to into the
activated trastuzumab (F(ab’)2-trastuzumab-SMCC). done 240-
241
…….. in the Multi-Purposes GA Siwabessy Reactor …..
done
243 …..by addition of hen, 2 mL of 6 M HCl. done
247 …… was re-dissolved in with 3 mL of HCl 0.05 M. done 251-
253
The solution of 177Lu was diluted with 0.25 M ammonium acetate at pH 7.5 (1:3), and then subsequently added into the (DOTA)m-PAMAM G 3.0- F(ab’)2-trastuzumab.
done
255- 256
……… to 5.5 with 0.1 N NaOH, and then it was incubated
for 90 min at 37 °C. done
259- 261
The reaction mixture from the radiolabelling process was
then loaded into a PD-10 column. done
261- 262
The column was then eluted using 0.01 M PBS at pH 7.4, and the eluent was collected and separated into 50 fractions (0.25 mL/ fraction).
done 265-
266
The fractions, which had high radioactivity, were then tested
for …. done
269- 270
……. saline solution were used as a stationary and mobile
phases, respectively. done
276- 294
This paragraph does not report and even discuss the experimental results. The content of this paragraph was mentioned in the experimental method section. If you think this paragraph is important, it is better you move it to the introduction section or to the experimental method section
This paragraph has been removed
295- 299
This statement was mentioned previously in the previous
sections. Please remove it. The statement has been removed
300- 301
The chromatograms chromatogram of standard proteins that
have passed the SEC column is shown in Figure 2.A. done 302-
304
This chromatogram shows 5 five peaks of protein standard five standard proteins with different molecular weight as indicated with each its retention time (RT).
done 304-
306
Figure 2B shows demonstrates the chromatogram of
trastuzumab that It has a molecular weight of ~148 kDa [13];. done
310 ….. while the Rt RT of the…. done
312- 314
It indicates is assumed that the data measured using the HPLC in this experiment agree with the reference data. (There is still uncertainty in this statement)
done 321-
322
between the second peak (_-globulin, MW 158 kDa KDa) and
the third peak (Ovalbumin, MW 44 kDa Kda). done
325 The measured results demonstrates demonstrate that….. done 327-
328
a small peak with a percent age percentage area of 5 %...
done 329-
330
…which is assumed corresponds to be the Fc portion that has
not been removed completely separated through the column done 374-
375
This synthesis reaction was carried out in consisted of the four stages as described in the previous section. : the first stage was preparation of NHS-DOTA-PAMAM G 3.0.
done
376- 381
The bifunctional chelating agent (BFCA) selected in this project was NHS-DOTA. The reason of the use of NHS-DOTA instead of p-SCN-Bn-DOTA for preparing the conjugate of NHS- DOTA-PAMAM G 3.0 due to its low solubility of (DOTA-p- SCN-Bn)n PAMAM-G3.0 conjugate after the freeze dry process as evidenced in the previous studies.is more advantageous than p-SCN-Bn-DOTA. Previous studies showed that after freeze dry process, the solubility of conjugate (DOTA-p-SCN-Bn)n PAMAM-G3.0 became low
done
382- 384
Therefore, it was not able impossible to be well re-constituted
completely the conjugate before its labeling with 177Lu [14]. done 384-
393
The next step stage of the synthesis was activation of conjugate dendrimers dendrimer conjugate, (DOTA)m-PAMAM G 3.0.
Activation of this conjugate with 2-iminothiolane was intended to provide a sulfhydryl group on the surface of (DOTA)m-
done
PAMAM G 3.0 which is going to be used for further coupling.
The resulted (DOTA)m-PAMAM G 3.0-SH was purified from unreacted 2-iminothiolane and other by-products By using a PD- 10 column (eluted with eluent of phosphate buffer 0.05 M at pH 7.4 containing EDTA 5mm).
401- 412
The color changes in this colorimetric assay are is due to the electrostatic interactions between the remaining primary amine groups of dendrimer and protonated one with one sulfo groups of Coomassie blue [12].
done
414- 432
The further step third stage of the synthesis was activation of F(ab')2-trastuzumab by reacting it with SMCC. maleimide This activation was intended to provide F(ab')2-trastuzumab with maleimide and F(ab')2-trastuzumab-SMCC, which is then coupled specifically with the sulfhydryls from of (DOTA)m- PAMAM G3.0-SH. Purification and testing for (DOTA)m- PAMAM G3.0-SH F(ab')2-trastuzumab-SMCC were was carried out in similar to that of (DOTA)m-PAMAM G3.0- sulfhydril. The results of a colorimetric assay of F(ab')2- trastuzumab-SMCC is shown in Figure 3B. The positive fractions containing trastuzumab-SMCC were fractions numbered 14-19. The results of a colorimetric assay of F(ab')2- trastuzumab-SMCC is shown in Figure 3B. The last step The fourth stage was the conjugation of DOTA-PAMAM G3.0–SH with F(ab')2-trastuzumab-SMCC to form a DOTA-PAMAM G3.0–F(ab')2-trastuzumab conjugate. The reaction mixture was incubated overnight, which was then dialyzed using slides A- Lyzer (20 K MWCO) with 0.25 M ammonium acetate at pH 7.2 containing 1.2 grams of Chelex-100.
done
434- 446
The complex formation of (177Lu-DOTA)m-PAMAM G3.0- F(ab')2-trastuzumab was performed by reacting a DOTA- PAMAM G3.0–F(ab')2-trastuzumab conjugate with 177Lu3+ at pH 5 - 5.5 with the incubation time of 90 minutes. At the end of Once the incubation time was complete, EDTA was added to the reacting mixture to bind to the free 177Lu3+, which was not bound to the DOTA-PAMAM G3.0-F(ab')2-trastuzumab [15]. Analysis of the labeling percentage of the (177Lu-DOTA)m-PAMAM G3.0 - F(ab')2-trastuzumab before and after passing through the column was determined using thin layer chromatography ( of ITLC-SG and saline solution as stationary and mobile phases, respectively).
done
456- 472
Figure 4A is a radiochromatogram of (177Lu-DOTA)m-PAMAM G3.0-F(ab')2-trastuzumab before passing through the PD-10 column. The presence of To determine whether the compound did not contain free 177Lu, (in the form of 177Lu-EDTA), was confirmed with a
radiochromatogram of the177Lu-EDTA,which was prepared separately and was also spotted on ITLC SG strips and developed with saline solution (see Fig. 4B).
Figure 4A and 4B show chromatograms of (177Lu-DOTA)m- PAMAM G3.0 - F(ab’)2-trastuzumab and free 177Lu (in the form of 177Lu -EDTA respectively. It can be seen that there was free
177Lu (Rf = 1) in the reacting reaction mixture that contain a main product of the (177Lu-DOTA)m-PAMAM G3.0-F(ab')2- trastuzumab (Rf = 0) that has . it is recognized by the presence of 177Lu peaks (Rf = 1) in the chromatogram of the 177Lu- DOTA-PAMAM G3.0-F(ab')2-trastuzumab (Rf = 0). These results are confirmed by calculation of the radiochemical purity
the standard deviation has been added
of , which is only 76.77%.(please, state the radiochemical purity with its standard deviation).
480- 493
Thus it was necessary to do the purification process. The purification of (177Lu-DOTA)m-PAMAM G3.0-F(ab')2- trastuzumab was carried out using the PD-10 column and the eluatet eluate was collected and separated into 50 fractions (in 0.25 mL each). The radioactivity of each fraction was measured using a dose calibrator [13]. its elution profile Elution profiles of the (177Lu-DOTA)m-PAMAM G3.0-F(ab')2-trastuzumab are is shown in Figure 5. It appears From these profiles, it is
understood that based on the 177Lu radioactivity there are two distinct peaks of ; the first peak is the complex of the (177Lu- DOTA)m-PAMAM G3.0-F(ab')2- trastuzumab and the second peak is bonded to a free 177Lu EDTA, respectively. Fractions which have high radioactivity were then tested for their radiochemical purity using the ITLC-SG..
done
493- 499
What do you mean with this statement “The selected fractions were fraction No. 14 and 15.”?? (see again carefully Fig. 5. Are the fractions No. 14 and 15 relevant?)
Please remove this very common statement “The radiochemical purity of the (177Lu–DOTA)m-PAMAM-F(ab’)2–trastuzumab was calculated based on the ratio between the count rate under the (177Lu–DOTA)m-PAMAM-F(ab’)2–trastuzumab peak and the total count rate”. If you think this statement is very
important, please move it to the Experimental Section.
-The statement “ the selected fraction were fraction no 14 and 15 has been removed. The radiochromatogram shown in Fig. 5 (The new number figure, based on advise from editor, we rearrange Fig. Number because because the figure number 1 does not exist) is derived from elution profile of fraction 12.
However the same radiochemical were resulted from different fractions after several trials.
Therefore we have modified the caption in Figures 4&5.
-The statement of “The radiochemical purity of the (177Lu–DOTA)m-PAMAM- F(ab’)2–trastuzumab …has been removed
500- 508
Figure 6 shows radiochromatograms an ITLC-SG
radiochromatogram of fraction 12 from the elution profile of Fig. 5. The radiochemical purity of fractions fraction No.12 as (177Lu-DOTA)m-PAMAM G3.0-F(ab')2-trastuzumab in the ITLC-SG radiochromatogram is found to be 98.18%.(please, state the radiochemical purity with its standard deviation as a measure of its uncertainty. Please also specify the impurity species of 1.82%). Experimental results showed that purification of (177Lu-DOTA)m-PAMAM F(ab')2–trastuzumab using a PD- 10 column was found to be effective in increasing the
radiochemical purity of (177Lu-DOTA)m-PAMAM-F(ab')2–
trastuzumab from 76.77% to 98.18%. It means there is a radiochemical purity increase of about 21.41%.
-it’s already added the explanation about impurity species of 1.64% and the standard deviation.
518- 533
The (177Lu)n-(DOTA)m-PAMAM-G3-F(ab')2-trastuzumab (177Lu-DOTA)m-PAMAM-G3-F(ab')2-trastuzumab, which will be expected to be potential as an RIT agent for therapy of breast cancer overexpressed HER-2, has been prepared successfully.
The F(ab')2-trastuzumab as a precursor of (177Lu)n-(DOTA)m- PAMAM-G3-F(ab')2-trastuzumab was prepared by enzymatic
done
digestion of intact trastuzumab using pepsin. The radiolabeling of (DOTA)m-PAMAM-G3.0-F(ab')2-trastuzumab with 177Lu at 37°C and incubation time of 90 min results in (177Lu)n- (DOTA)m-PAMAM-G3-F(ab')2-trastuzumab (177Lu-DOTA)m- PAMAM-G3-F(ab')2-trastuzumab with the radiochemical purity of 98% after purification with PD-10 column. The stability and other tests (in vitro and in vivo) of the (177Lu)n-(DOTA)m- PAMAM-G3.0-F(ab')2 (177Lu-DOTA)m-PAMAM-G3-F(ab')2- trastuzumab and other tests (in vitro and in vivo) will be published reported shortly.
Please return to Atom Indonesia Editorial Office via e-mail: [email protected] and Faximile: 021-7560895.
This original sheet should be returned to:
Administrator Atom Indonesia, PPIKSN-BATAN, Gedung 71, Lantai 1, Kawasan Puspiptek Serpong, Tangerang, Indonesia 15310
Author Signature(s) Date
Name(s) (print)
